Annexon, Inc. (ANNX) vs 4D Molecular Therapeutics, Inc. (FDMT)

Annexon, Inc. and 4D Molecular Therapeutics, Inc. are both Biotechnology companies. Annexon, Inc. and 4D Molecular Therapeutics, Inc. are of similar size ($711.0M and $682.5M). Annexon, Inc. has the higher net margin (0.00% vs −194.7%) and the higher return on invested capital (0.00% vs −186.9%). Across the 14 metrics below, 4D Molecular Therapeutics, Inc. leads on 8 and Annexon, Inc. on 6.

Valuation

Metric ANNX FDMT Biotechnology median
P/E n/m n/m 8.50
P/S n/m 9.27 9.71
P/B 3.68 2.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 5.56 9.21
Earnings yield (34.02%) (21.66%) (33.15%)
Free cash flow yield (28.19%) (18.28%) (25.50%)

Profitability

Metric ANNX FDMT Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (214.24%) 0.00%
Net margin 0.00% (194.74%) 0.00%
Free cash flow margin 0.00% (169.51%) 0.00%
Return on equity (105.26%) (43.25%) (56.36%)
Return on assets (79.38%) (37.09%) (48.04%)
Return on invested capital 0.00% (186.91%) 0.00%

Growth

Metric ANNX FDMT Biotechnology median
Revenue growth (TTM) — 278,712.12% 6.02%
EPS growth (last fiscal year) (32.67%) 18.79% 30.26%
Revenue growth, 5-year CAGR — 44.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANNX FDMT Biotechnology median
Debt to equity 0.00 0.05 0.00
Current ratio 5.53 8.03 4.72
Net debt to EBITDA 1.11 2.52 0.96

Dividend

Metric ANNX FDMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ANNX FDMT Biotechnology median
Market cap 682.49m 710.99m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack